CN110257358B - Production method of high-purity human coagulation factor IX preparation - Google Patents

Abstract

The invention discloses a method for producing a high-purity human coagulation factor IX preparation with few process steps, low production cost and high specific activity. The method comprises the following steps: (1) plasma cryoprecipitation removal; (2) DEAE sephadex a50 anion exchange chromatography; (3) S/D inactivating virus; (4) non-Ca²⁺ Dependent factor IX immunoaffinity chromatography; (5) adding a protective agent into the prepared liquid; (6) nanofiltration membrane virus removal filtration; and (7) sub-packaging and freeze-drying. The invention greatly simplifies the production process of the human blood coagulation factor IX by adopting the novel immunoaffinity chromatography with high adsorption specificity, and the titer of the prepared high-purity human blood coagulation factor IX finished product can reach 114.2IU/ml, and the specific activity of the IX factor can reach more than 196.5IU/mg protein; in addition, the invention adopts the S/D method and the nanofiltration method with high maturity and safety to carry out two-step virus inactivation, thereby effectively ensuring the safety of the product.

Description

Production method of high-purity human coagulation factor IX preparation

Technical Field

The invention belongs to the technical field of biological pharmacy and blood products, and in particular relates to a method for producing a high-purity human coagulation factor IX preparation with few process steps, low production cost and high specific activity in blood product production.

Background

Human coagulation factor IX (human coagulation factor IX, hFIX) is a key acting coagulation factor, belongs to a vitamin K dependent glycoprotein, is a precursor of serine protease in the human endogenous coagulation cascade, and plays a very important role in the human endogenous coagulation pathway.

Hemophilia b is a rare genetic disease with a morbidity of about 1/25000. Hemophilia b is caused by the absence of factor IX, and patients require an extremely long time to coagulate once they bleed. Some minor injuries may have sufficient life threatening impact. For patients with serious illness, the joints and muscles of the patients can bleed spontaneously and frequently, and pain is brought. The current mainstay therapy for this disease is the use of human prothrombin complex (Prothrombin Complex Concentrate, PCC) infusion therapy to control and prevent bleeding events.

However, when PCC is used for treating hemophilia B or deficiency of blood coagulation factor IX, because PCC contains vitamin K-dependent blood coagulation factors II I, V II, IX, X, protein C, protein S, a-trypsin inhibitor, high molecular weight kininogen and the like, large dosage of PCC may cause thrombosis and disseminated intravascular coagulation, and a certain risk exists. Therefore, the high-purity blood coagulation factor IX product separated from the blood plasma can effectively control the bleeding condition of a patient, obviously reduce the risk of thrombus occurrence in the process of medication of the patient, has quite large market prospect, and has extremely high research enthusiasm for the high-purity blood coagulation factor IX product at home and abroad. With the gradual acceptance by clinicians, the use of highly pure factor IX products is increasing year by year; at present, high-purity blood coagulation factor IX products derived from plasma are not marketed in China, and raw material plasma is tense, so that the market shortage of the high-purity blood coagulation factor IX products derived from plasma is brought about, and the production and preparation of the high-purity blood coagulation factor IX products are concerned in various aspects.

Cai Jun et al reported in the "column chromatography preparation of high purity human blood FIX study initial probes" a method for preparing high purity blood coagulation factor IX with DEAE Sephadex a50, DEAE-Sepharose FF and Heparin-Sepharose CL-6B, the final specific activity of the blood coagulation factor IX product was 35±2.0IU/mg, and the recovery was about 30%. Zhao Yanding et al in the "chromatography separation of human plasma coagulation factor IX from self-made filling medium" adopted self-made DEAE Bio-Sep FF and heparin Bio-Sep medium, through 2 steps of weak anion exchange and 1 step of affinity chromatography, separated and purified coagulation factor IX from cryoprecipitated plasma, the specific activity of the finished product reached 99.40IU/mg, and the recovery rate was about 30%. The above methods all use 2-step anion exchange and 1-step heparin affinity chromatography to purify coagulation factor IX, but the product yields are still good, but since heparin ligand filler development was originally intended as an AT-III adsorbent, the gel was specific for AT-III, coagulation factors (including VIII, IX), lipoproteins, lipases, protein synthesis factors; the hormone, steroid receptor, nucleic acid binding enzyme, restriction endonuclease, interferon and other tens of protein types have adsorption effect, and the adsorption specificity of the human blood coagulation factor IX is not strong, so that the specific activity of the human blood coagulation factor IX finished product prepared by the preparation process is low, even the minimum requirement that the specific activity is not lower than 50IU/mg in European pharmacopoeia can not be met, and therefore, the preparation process has no mass production value.

The publication No. 2008.10.22, publication No. CN101291951A, discloses a preparation method for purifying human IX clotting factor from plasma source by utilizing 2 times of anion exchange chromatography, heparin affinity chromatography and cation exchange chromatography, wherein the specific activity is improved by adding chromatographic process steps, and the prepared human IX clotting factor has higher specific activity which can reach 150IU/mg. However, as the production process is complicated and needs to go through 4 times of chromatography steps, the technical personnel in the field know that the target protein is inevitably lost after going through 1 times of chromatography and purification steps, so that the product yield of the preparation process is lower; in addition, the 4 times of chromatography steps are required to consume a large amount of gel filler, so that the production cost is extremely high, and the method is not convenient for large-scale popularization.

In view of the above, there is a need in the market for a method for manufacturing a highly pure factor IX product with low process steps, low production costs, and high specific activity, to meet the requirements of clinical patients to the maximum extent and to increase the plasma utilization rate to the maximum extent.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provide a method for producing a high-purity human coagulation factor IX preparation with few process steps, low production cost and high specific activity. In order to achieve the purpose, the invention adopts the following technical scheme.

A method for producing a highly pure human coagulation factor IX formulation, comprising the steps of:

(1) Removal of plasma cryoprecipitation: taking fresh frozen human plasma as a raw material, removing cryoprecipitate in the plasma through the procedures of slurry melting, slurry mixing, continuous centrifugation and the like, and obtaining plasma supernatant without cryoprecipitate;

(2) Ion exchange gel adsorption: the temperature of the plasma is controlled at 10-15 ℃, and the balanced DEAE-sephadex A-50 gel is added into the cryoprecipitated plasma according to 1.0-1.5g xerogel/L plasma, and the mixture is stirred and adsorbed for 45min, then the stirring is closed, and the mixture is settled for 45min. Filtering the plasma after gel adsorption by using a continuous filter, collecting the A-50 gel after adsorption, and merging the plasma filtrate into a plasma tank;

(3) Loading and eluting: filling the adsorbed A-50 gel into a fixed bed chromatographic column, pumping the filled chromatographic column into a washing liquid for online washing, wherein the flow rate of the washing liquid is 30-40cm/h, and the washing time is about 60-90min. The washed A-50 gel is eluted on line by using eluent with the flow rate of 30-40cm/h, the elution is stopped after the ultraviolet absorption value in the on-line ultraviolet detector is lower than 500mAu, and the eluent is collected and filtered by using a 0.45um filter element;

(4) S/D inactivated virus: slowly adding the prepared S/D inactivating liquid into the filtered eluent under mild stirring, and stirring for 30min after the addition. Regulating the liquid temperature to 24-26 ℃ and inactivating for 6 hours;

(5) Affinity chromatography: agarose immune affinity gel is filled in a fixed bed chromatographic column, the filled chromatographic column balances 5-10 column volumes by using balance liquid, and feed liquid after S/D inactivation flows into the chromatographic column, and the loading flow rate is 50-80cm/h. And (3) after the sample loading is finished, performing compound washing by using two different washing solutions, wherein the flow rate of the washing solution is 50-80cm/h. Eluting the washed chromatographic column by using an eluent with the flow rate of 50-80cm/h, stopping eluting after the ultraviolet absorption value in the online ultraviolet detector is lower than 100mAu, and collecting the eluent;

(6) Preparing liquid: adding a protective agent to the eluent, wherein the protective agent is a salt, a sugar, an amino acid or a mixture thereof; diluting the eluent with diluent, adjusting the activity to 30-40IU/ml, and filtering with 0.45um filter element, wherein the pH is 7-7.5;

(7) Nanofiltration membrane virus removal and filtration;

(8) Packaging, and freeze drying to obtain high-purity human blood coagulation factor IX preparation.

Further, the washing liquid in the step (3) is a washing buffer solution A containing 20-30mmol/L sodium citrate, 0.1-0.5mol/L sodium chloride, 200-500IU/ml heparin sodium and having a pH of 6.8-7.0; preferably a wash buffer containing 25mmol/L sodium citrate, 0.25mol/L sodium chloride, 200IU/ml heparin sodium, pH 6.9.

Further, the eluent in the step (3) is an elution buffer A containing 20-30mmol/L sodium citrate, 0.5-1.0mol/L sodium chloride, 200-500IU/ml heparin sodium and having a pH of 6.8-7.0; preferably an elution buffer containing 25mmol/L sodium citrate, 0.8mol/L sodium chloride, 200IU/ml heparin sodium, pH 6.9.

Further, the affinity chromatography medium in the step (5) is agarose immune affinity gel; preferably, non-Ca is used² + dependent factor IX immunoaffinity gel with a gel dose of 0.5ml/kg plasma.

Further, the complex washing in the step (5) is 3 times of stepwise washing by using two different washing buffers. Washing 1 st time: washing 8-12 column volumes with a washing buffer B containing 10-30mmol/L Tris,0.1-0.15mol/L sodium chloride, pH 6.8-7.5; preferably, 8 column volumes are washed with washing buffer B containing 20mmol/L Tris,0.15mol/L sodium chloride, pH 7.4. Washing for the 2 nd time: washing 8-12 column volumes with a wash buffer C containing 10-30mmol/L Tris,0.4-0.6mol/L sodium chloride, 0.05-0.1% Tween-80, pH 6.8-7.5; preferably, 8 column volumes are washed with washing buffer C containing 20mmol/L Tris,0.6mol/L sodium chloride, 0.05% Tween-80, pH 7.4. Washing for the 3 rd time: washing 8-12 column volumes with a washing buffer B containing 10-30mmol/L Tris,0.1-0.15mol/L sodium chloride, pH 6.8-7.5; preferably, 4 column volumes are washed with washing buffer B containing 20mmol/L Tris,0.15mol/L sodium chloride, pH 7.4.

Further, the eluent in the step (5) is an elution buffer B containing 10-30mmol/L Tris, O-2mol/L magnesium chloride, 0-0.2mol/L glycine and pH 2-7.5; preferably, the eluent is an elution buffer containing 10mmol/L Tris,0.2mol/L glycine and having a pH of 5.5.

Further, the active protective agent in the step (6) is a mixed protective agent of salt, sugar and amino acid; preferably, the active protective agent is a mixed protective agent of sucrose, lysine, arginine, glycine and sodium citrate; more preferably, the active protective agent is a mixed protective agent containing 2-5% of sucrose, 1-3% of lysine, 1-3% of arginine, 1-3% of glycine and 20mmol/L of sodium citrate.

Further, the nanofiltration membrane in the step (7) is a hollow regenerated cellulose nanofiltration membrane, and preferably a PLANOVA 20N nanofiltration membrane is used for virus removal filtration.

The human blood coagulation factor IX product prepared by the method for producing the high-purity human blood coagulation factor IX preparation.

Compared with the prior art, the invention has the following beneficial effects:

1. AT present, the method of ion exchange chromatography and heparin affinity chromatography is mainly used for purifying the blood coagulation factor IX in China, and because heparin affinity filler is initially used as an AT-III adsorbent, the gel has adsorption effect on various protein types such as AT-III, blood coagulation factors (including VII, IX), lipoprotein and the like, and has weak adsorption specificity on human blood coagulation factor IX, the finished product of the human blood coagulation factor IX prepared by adopting the conventional 3-step chromatography has lower specific activity and can not meet the European pharmacopoeia requirements; the adoption of the purification step to increase the specific activity will tend to reduce the product yield and increase the production cost.

The invention adopts novel non-Ca with high adsorption specificity² + dependent factor IX immunoaffinity chromatography greatly simplifies the traditional process of human coagulation factor IX. non-Ca² The immune affinity filler of the +dependent factor IX adopts monoclonal antibody fragments of specific affinity human blood coagulation factor IX molecules as ligands, and is formed by connecting spherical agarose particles (matrixes), and has extremely high adsorption specificity and adsorption capacity on the human blood coagulation factor IX molecules, and no Ca exists in 1 step² + dependent factor IX immunoaffinity chromatography can be substituted for multi-step chromatographyThe original 3-step chromatography process is simplified into 2-step chromatography on the basis of not affecting the specific activity of the finished product, the gel consumption is reduced by more than 70%, the material and time cost is obviously reduced, and the comprehensive production cost is reduced by more than 3 times compared with the traditional process. Meanwhile, the specific activity of the obtained human blood coagulation factor IX finished product is not reduced and reversely increased, the titer of the IX can reach more than 114.2IU/ml, and the specific activity of the IX can reach more than 196.5IU/mg protein, which is far higher than European pharmacopoeia standard.

2. In the affinity elution chromatography process, the preferred elution buffer solution containing 10-30mmol/L sodium citrate, 0-0.2mol/L glycine and pH of 2-7.5 is used for eluting, and all target proteins can be completely eluted only by 3 column volumes, so that the elution effect is excellent; meanwhile, due to the simple components of the elution buffer, EDTA buffer solution needed in the conventional immunoaffinity chromatography elution process is avoided, potential toxic substances are reduced, and the safety of the product is effectively ensured.

3. Because the optimized sucrose, lysine, arginine, glycine and sodium citrate mixed active protective agent is adopted, the high-purity human coagulation factor IX preparation finished product prepared by the preparation method disclosed by the invention has short redissolution time, can be completely redissolved within 3min, is far lower than the quality standard of 30min in redissolution time, has good redissolution effect, and the redissolution is clarified to be slightly opalescent.

4. Novel non-Ca employed in the present invention² The + dependent factor IX immunoaffinity filler, the ligand manufacture, culture and purification processes of which are all performed in the absence of mammalian components, does not risk the introduction of exogenous animal components. Meanwhile, the S/D method and nanofiltration method with high maturity, simplicity and safety are adopted in the production process of the blood coagulation factor IX preparation of the inventor to carry out two-step virus inactivation, so that the safety of the product is effectively ensured.

Drawings

FIG. 1 is a process flow diagram of a process for producing a high purity human factor IX preparation from plasma;

FIG. 2 is an SDS-page electrophoresis image of the finished product of the high purity human factor IX preparation of example 2.

Detailed Description

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification taken in conjunction with the drawings. The examples provided are merely illustrative of the methods of the present invention and are not intended to limit the remainder of the disclosure in any way whatsoever.

[ example 1 ]

Removal of plasma cryoprecipitation: taking fresh frozen human plasma as a raw material, removing cryoprecipitate in the plasma through the procedures of pulp melting, pulp mixing, continuous centrifugation and the like to obtain 2kg of plasma supernatant without cryoprecipitate;

gel batch adsorption: the plasma temperature was controlled at 15℃and 1.5g xerogel/L plasma was added to the cryoprecipitated plasma with equilibrated DEAEA-50 gel, and the stirring was turned off after 45min of adsorption with stirring. Filtering the plasma after gel adsorption by using a small-sized closed filter, and collecting the A-50 gel after adsorption;

loading and eluting: filling the adsorbed A-50 gel into a small XK16/20 chromatographic column, and washing the filled chromatographic column on line by using an AKTA chromatographic system, wherein the flow rate of washing liquid is 2ml/min, and the washing time is 50min. The washed A-50 gel is switched to perform online elution, the flow rate of the eluent is 2ml/min, the elution is stopped after the ultraviolet absorption value in an online ultraviolet detector is lower than 500mAu, 125ml of the eluent is collected, and the eluent is filtered by using a small-sized 0.45um filter element;

S/D inactivation: slowly adding the prepared S/D inactivating liquid into the filtered eluent under mild stirring, and stirring for 30min after the addition. Regulating the liquid temperature to 24 ℃ and inactivating for 6 hours;

affinity chromatography: will not be Ca² 10ml of the + dependent IX factor immunoaffinity gel is filled in a small XK16/20 chromatographic column, the filled chromatographic column is pumped into 20mmol/L Tris,0.15mol/L sodium chloride and buffer solution with pH of 7.4 by using an AKTA chromatographic system, 10 column volumes are balanced, and after S/D inactivation, the feed liquid flows into the chromatographic column, and the loading flow rate is 2ml/min. After loading was completed, washing was performed 3 times using two different wash buffers at a wash flow rate of 2ml/min. Washing 1 st time: 80ml of the washing buffer having a pH of 7.4 was washed with a solution containing 20mmol/L Tris,0.15mol/L sodium chloride. Washing for the 2 nd time: washing with 20mmol/L Tris,0.6mol/L sodium chloride, 0.1% Tween-80, pH 7.480ml of the washing solution was washed. Washing for the 3 rd time: 30ml of the washing buffer having a pH of 7.4 was washed with a solution containing 20mmol/L Tris,0.15mol/L sodium chloride. Eluting the washed chromatographic column by using an eluting buffer solution containing 10mmol/L of Tris,2mol/L of magnesium chloride and pH of 7.5, wherein the flow rate of the eluting solution is 2ml/min, stopping eluting after the ultraviolet absorption value in an online ultraviolet detector is lower than 100mAu, and collecting 80ml of eluting solution altogether;

preparing liquid: adding 20ml of mixed protective agent containing 3% of sucrose, 2% of lysine, 2% of arginine, 2% of glycine and 20mmol/L of sodium citrate into the eluent; detecting, namely, the titer of the crude blood coagulation factor IX is 23.4IU/ml, diluting the eluent by using a diluent, adjusting pH7.5, filtering by using a 0.45um filter head, and collecting 100ml of filtrate altogether;

and (5) subpackaging and freeze-drying: subpackaging according to the specification of 10.5 ml/bottle, and freeze-drying to obtain 7 bottles of high-purity human coagulation factor IX preparation finished products.

[ example 2 ]

Removal of plasma cryoprecipitation: taking fresh frozen human plasma as a raw material, removing cryoprecipitate in the plasma through the procedures of slurry melting, slurry mixing, continuous centrifugation and the like, and obtaining 4kg of plasma supernatant without cryoprecipitate;

gel batch adsorption: the plasma temperature was controlled at 10℃and 1.0g xerogel/L plasma was added to the cryoprecipitated plasma with equilibrated DEAEA-50 gel, and the stirring was turned off after 45min of adsorption with stirring. Filtering the plasma after gel adsorption by using a small-sized closed filter, and collecting the A-50 gel after adsorption;

loading and eluting: filling the adsorbed A-50 gel into a small XK16/20 chromatographic column, and washing the filled chromatographic column on line by using an AKTA chromatographic system, wherein the flow rate of washing liquid is 2ml/min, and the washing time is 60min. The washed A-50 gel is switched to perform online elution, the flow rate of the eluent is 2ml/min, the elution is stopped after the ultraviolet absorption value in an online ultraviolet detector is lower than 500mAu, the eluent is collected to 340ml, and the eluent is filtered by a small-sized 0.45um filter element;

S/D inactivation: slowly adding the prepared S/D inactivating liquid into the filtered eluent under mild stirring, and stirring for 30min after the addition. Regulating the liquid temperature to 24 ℃ and inactivating for 6 hours;

affinity chromatography: will not be Ca² 12ml of the + dependent IX factor immunoaffinity gel is filled in a small XK16/20 chromatographic column, the filled chromatographic column is pumped into 20mmol/L Tris,0.1mol/L sodium chloride and buffer solution with pH of 7.4 by using an AKTA chromatographic system, 10 column volumes are balanced, and after S/D inactivation, the feed liquid flows into the chromatographic column, and the loading flow rate is 2ml/min. After loading was completed, washing was performed 3 times using two different wash buffers at a wash flow rate of 2ml/min. Washing 1 st time: 100ml of the washing buffer was washed with a solution containing 20mmol/L Tris,0.1mol/L sodium chloride and pH 7.4. Washing for the 2 nd time: 100ml of the washing buffer containing 20mmol/L Tris,0.6mol/L sodium chloride, 0.05% Tween-80 and pH 7.4 was used. Washing for the 3 rd time: 50ml of the washing buffer having a pH of 7.4 was washed with a solution containing 20mmol/L Tris,0.1mol/L sodium chloride. Eluting the washed chromatographic column by using an eluting buffer solution containing 10mmol/L of Tris,0.2mol/L of glycine and pH of 5.5, wherein the flow rate of the eluting solution is 2ml/min, stopping eluting after the ultraviolet absorption value in an online ultraviolet detector is lower than 100mAu, and collecting 45ml of eluting solution altogether;

preparing liquid: adding 10ml of mixed protective agent containing 5% of sucrose, 3% of lysine, 3% of arginine, 3% of glycine and 20mmol/L of sodium citrate into the eluent; through detection, the titer of the original blood coagulation factor IX is 114.2IU/ml, the eluent is diluted by using a diluent, the activity is regulated to be 30IU/ml, the pH is 7.5, the solution is filtered by using a 0.45um filter head, and the total concentration of the filtrate is 210ml;

nanofiltration virus: adopting a PLANOVA 20N nanofiltration membrane to remove viruses and filter;

and (5) subpackaging and freeze-drying: subpackaging according to the specification of 10.5 ml/bottle, and freeze-drying to obtain 18 bottles of high-purity human coagulation factor IX preparation finished products.

[ example 3 ]

The high purity human coagulation factor IX preparation finished product prepared in example 2 was subjected to SDS-page electrophoresis by a commission detection laboratory to determine the distribution of the major protein species in the finished product. The detection operation steps are as follows:

(1) Washing and airing the glass plate;

(2) The glass plate is fixed on the glue filling bracket, and the force is uniform on both sides during fixing, so that the glass plate is prevented from being damaged;

(3) Preparing 8% of separating gel according to a proportion, rapidly adding by a pipette, adding about 1cm above the separating gel, adding a little water for sealing at night, and standing for about 40min;

(4) Pouring out water, sucking the residual water with filter paper, preparing 5% concentrated gel, continuously and stably adding concentrated gel to the position 5mm away from the edge, rapidly inserting a sample comb, and standing for 30-40min;

(5) After adding buffer solution in the upper tank, extracting the sample comb to discharge bubbles completely;

(6) Adding a sample, namely taking 4 times of protein sample dissolving solution into an EP tube, and adding 1 time of sample buffer solution (5X), wherein the sample adding amount is 10 microliters; directly dissolving and loading a marker;

(7) Heating the sample in boiling water for 3min before sample addition to remove metastable state polymerization;

(8) The height should be controlled during sample addition to prevent diffusion or edge effect;

(9) Adding buffer solution into the electrophoresis tank, switching on power supply, performing electrophoresis, controlling voltage at 80V at the beginning, changing into 121V after entering into separation gel, and stopping electrophoresis when bromophenol blue is about 5mm away from gel edge;

(10) After electrophoresis, the glass plate is pried open, the gel plate is marked and then is placed in a large culture dish, the dyeing liquid is added for dyeing for about 10min, and the decoloring liquid is used for decoloring until the protein zone is clear.

SDS-page electrophoresis detection results show that the main protein band positions of the finished human blood coagulation factor IX preparation prepared in the example 2 are basically consistent with those of the human blood coagulation factor IX standard, and the mixed protein bands are almost invisible, so that the finished human blood coagulation factor IX preparation prepared in the example 2 is higher in purity and less in mixed protein type.

[ example 4 ]

Examples 1 and 2 and another batch of human factor IX lyophilized finished product were tested for all items.

The test laboratory was commissioned to perform a full-project test on lyophilized finished human factor IX products produced in examples 1 and 2 and another batch, the test project set up was referenced to the quality standard of finished human factor IX products in the european pharmacopoeia 8.0, and the test results are shown in table 1: the 3 batches of products are qualified in all quality indexes, have high titer and high specific activity, and the factor IX of the finished product is more than 20IU/ml, has the specific activity as high as 196.5IU/mg and almost does not contain impurities such as coagulation factors II, VII, X and the like; meanwhile, the product has high redissolution speed of only 3min, is far lower than the quality standard that the redissolution time is less than 30min, has good redissolution effect, and the redissolution is clear and only has slight opalescence.

TABLE 1 full program detection results of human coagulation factor IX finished products

Claims (1)

1. A method for producing a highly pure human coagulation factor IX formulation, comprising the steps of:

removal of plasma cryoprecipitation: taking fresh frozen human blood plasma as a raw material, removing cryoprecipitate in the blood plasma through the procedures of pulp melting, pulp mixing, continuous centrifugation and the like;

gel batch adsorption: the temperature of the plasma is controlled at 10 ℃, balanced DEAE A-50 gel is added into cryoprecipitated plasma according to 1.0g xerogel/L plasma, stirring and adsorbing are carried out for 45min, stirring is closed, the plasma after gel adsorption is filtered by a small-sized closed filter, and the A-50 gel after adsorption is collected;

loading and eluting: filling the adsorbed A-50 gel into a small XK16/20 chromatographic column, online washing the filled chromatographic column by using an AKTA chromatographic system, wherein the flow rate of a washing solution is 2ml/min, the washing time is 60min, online eluting the washed A-50 gel by switching an eluent, the flow rate of the eluent is 2ml/min, stopping eluting after the ultraviolet absorption value in an online ultraviolet detector is lower than 500mAu, and filtering by using a small 0.45um filter element;

S/D inactivation: slowly adding the prepared S/D inactivating liquid into the filtered eluent under mild stirring, stirring for 30min after adding, adjusting the liquid temperature to 24 ℃, and inactivating for 6h;

affinity chromatography: 12ml of non-Ca2+ -dependent IX factor immunoaffinity gel is filled in a small XK16/20 chromatographic column, the filled chromatographic column is pumped into a buffer solution containing 20mmol/L of Tris and 0.1mol/L of sodium chloride by using an AKTA chromatographic system, the buffer solution with the pH value of 7.4 balances 10 column volumes, the S/D inactivated feed liquid flows into the chromatographic column, the loading flow rate is 2ml/min, two different washing buffer solutions are used for washing for 3 times after the loading is finished, the flow rate of the washing solution is 2ml/min, and the 1 st washing: 100ml of the washing buffer with pH 7.4 was washed with 20mmol/L Tris,0.1mol/L sodium chloride, 2 nd washing: 100ml of the washing buffer with 20mmol/L Tris,0.6mol/L sodium chloride, 0.05% Tween-80, pH 7.4, washing 3 rd: washing 50ml of the washed chromatographic column by using a washing buffer solution containing 20mmol/L of Tris,0.1mol/L of sodium chloride and pH 7.4, and eluting the washed chromatographic column by using an eluting buffer solution containing 10mmol/L of Tris,0.2mol/L of glycine and pH 5.5, wherein the flow rate of the eluting solution is 2ml/min;

preparing liquid: adding 10ml of mixed protective agent containing 5% of sucrose, 3% of lysine, 3% of arginine, 3% of glycine and 20mmol/L of sodium citrate into the eluent, diluting the eluent by using a diluent, adjusting the activity to 30IU/ml, adjusting the pH to 7.5, and filtering by using a 0.45um filter head;

nanofiltration virus: adopting a PLANOVA 20N nanofiltration membrane to remove viruses and filter;

and (5) subpackaging and freeze-drying: subpackaging according to the specification, and freeze-drying.

Images